

# The use of a smartphone app to detect changes in health from voice recordings of people with cystic fibrosis

<b>Submission date</b> 05/05/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 15/08/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 19/12/2024	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Sonde Health is a health technology company with a platform that provides voice-enabled health detection and monitoring capabilities for brain, respiratory and muscular impairment. Analysis of vocal biomarkers can give early insight into health and wellness. Sonde enables most companies and developers with Android or iOS mobile applications to integrate health condition detection and monitoring capabilities powered by voice.

Royal Papworth Hospital has demonstrated that daily recordings of a range of physiological parameters (e.g. spirometry, pulse oximetry, activity, heart rate, etc) in combination with self-reported survey responses (e.g. general wellness, cough, sleep quality) in people with cystic fibrosis (CF) holds promise to more accurately track fluctuations in health condition, in particular the start of pulmonary exacerbations. These data are collected remotely at the study participant's home using remote/virtual online tools, as part of a larger effort to take a more virtual approach to clinics. Smartphone-based collection of voice samples for vocal biomarker analysis is a natural extension of this approach.

The aim of this study is to explore the potential of vocal biomarkers to assist in or improve the detection of health conditions in people with CF. The emphasis is on identifying the onset and progression of pulmonary exacerbations.

### Who can participate?

Patients who are 18 years old or over who have a diagnosis of cystic fibrosis, are able to perform home monitoring and are already using the Project Breathe remote monitoring kit

### What does the study involve?

Participants will be asked to do a daily voice recording of an 'ahhh' sound twice into an app downloaded onto a personal smartphone. They will also need to continue to use the Project Breathe home monitoring kit, which includes weighing scales, lung function spirometer, activity watch and recording self-reported measures of coughing and wellness. Participants will be enrolled for 1 year and it will have no impact on usual care.

What are the possible benefits of participating?

There are no potential immediate benefits to taking part but if the study proves successful it has the potential to improve the early diagnosis of pulmonary exacerbations at home. There are no known risks to taking part.

Where is the study run from?

Royal Papworth NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

January 2021 to December 2026

Who is funding the study?

1. Cystic Fibrosis Trust (UK)

2. LifeArc (UK)

Who is the main contact?

Prof. Andres Floto, arf27@cam.ac.uk

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Andres Floto

### ORCID ID

<https://orcid.org/0000-0002-2188-5659>

### Contact details

Royal Papworth Hospital

Papworth Road

Cambridge

United Kingdom

CB2 0AY

+44 (0)1223 638000

arf27@cam.ac.uk

### Type(s)

Public

### Contact name

Mrs Lucy Gale

### ORCID ID

<https://orcid.org/0000-0002-5697-810X>

### Contact details

Royal Papworth Hospital

Papworth Road

Cambridge

United Kingdom  
CB2 0AY  
+44 (0)1223638000  
lucy.gale1@nhs.net

**Type(s)**  
Scientific

**Contact name**  
Mrs Lucy Gale

**Contact details**  
Royal Papworth Hospital  
Papworth Road  
Cambridge  
United Kingdom  
CB2 0AY  
+44 (0)1223 638000  
lucy.gale1@nhs.net

## **Additional identifiers**

**Clinical Trials Information System (CTIS)**  
Nil known

**Integrated Research Application System (IRAS)**  
289665

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
P02706, IRAS 289665

## **Study information**

**Scientific Title**  
VOICE-CF: Vocal Biomarker Analysis for Health Condition Detection in People with Cystic Fibrosis

**Acronym**  
VOICE-CF

**Study objectives**  
The aim of this study is to explore the potential of vocal biomarkers to assist in or improve the detection of health conditions in people with cystic fibrosis. The emphasis is on identifying the onset and progression of pulmonary exacerbations and to evaluate whether daily respiratory symptom risk monitoring can assist the remote care of patients with cystic fibrosis.

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**

Approved 19/02/2021, North East - Newcastle & North Tyneside 1 Research Ethics Committee (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44 (0)2071048285; newcastlenorthtyneside1.rec@hra.nhs.uk), ref: 21/NE/0013

**Study design**

Single-centre observational prospective cohort study

**Primary study design**

Observational

**Study type(s)**

Other

**Health condition(s) or problem(s) studied**

Cystic fibrosis

**Interventions**

Participants will complete two daily voice recordings on the Sonde app using a personal smartphone. Each daily voice sample will take approximately 1 minute to complete a 6-second held vowel "ahhh." Participants will also continue with usual home monitoring such as weight, lung function, activity and self-reported measures as part of the Project Breathe study.

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Sonde smartphone app

**Primary outcome(s)**

The accuracy of the Sonde predictive algorithm to predict when antibiotics will be required to treat an acute pulmonary exacerbation. This will be from the sensitivity and specificity of the predictive algorithm when compared to the Project Breathe predictive algorithm over a 12-month period.

**Key secondary outcome(s)**

The accuracy of the Sonde predictive algorithm to substitute for spirometry and pulse oximetry. This will be from the sensitivity and specificity of the Sonde predictive algorithm when compared to spirometry and pulse oximetry over a 12-month period.

**Completion date**

31/12/2026

**Eligibility****Key inclusion criteria**

1. Diagnosis of cystic fibrosis based on genetic testing and/or sweat chloride levels
2. Age between  $\geq 18$  to  $\leq 65$  years of age at time of consent
3. Able to provide written informed consent
4. Patients who are currently undertaking home monitoring/virtual clinics
5. Patients who have the use of a smartphone

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

All

**Total final enrolment**

41

**Key exclusion criteria**

1. Patients unable to provide written informed consent
2. Patients who are currently not undertaking home monitoring/virtual clinics
3. Lung transplant recipients

**Date of first enrolment**

21/06/2021

**Date of final enrolment**

25/02/2022

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Royal Papworth Hospital NHS Foundation Trust

Papworth Road

Cambridge Biomedical Campus

Cambridge  
United Kingdom  
CB2 0AY

## Sponsor information

### Organisation

Royal Papworth NHS Foundation Trust

## Funder(s)

### Funder type

Charity

### Funder Name

Cystic Fibrosis Trust

### Alternative Name(s)

Cystic Fibrosis, cystic fibrosis (CF), CF

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Trusts, charities, foundations (both public and private)

### Location

United Kingdom

### Funder Name

LifeArc

### Alternative Name(s)

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Other non-profit organizations

### Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date. The datasets generated and/or data analysed during the current study are not expected to be made available until the end of all of the home monitoring studies that are currently underway/planned by this group.

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			20/09/2023	No	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Protocol file</a>	version 3.0	19/03/2021	17/05/2023	No	No